Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Maryland for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Maryland only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Maryland (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

William Sharfman (NPI 1760413652)

Field	Value
Entity Type	Individual
Organization	William Sharfman
Address	10755 Falls Rd
City	Lutherville
State	MD
ZIP	21093
Taxonomy	Medical Oncology Physician
NPI Enumerated	July 6, 2006

Payer Source	Total Paid
Medicare	$9.1M
Medicaid	$0

Key Findings

This provider is effectively a Medicare-focused oncology practice: lifetime Medicare revenue totals $9.1M while there is none below — this provider has no Medicaid billing on file, making the practice highly concentrated on Medicare reimbursement and exposure to that single payer. The volume and revenue mix point to a business model built around administration of high-cost oncology biologics rather than broad Medicaid-covered services.

Revenue concentration is pronounced: the precomputed top 3 Medicare codes account for 69.4% of total Medicare revenue, with J9298 contributing $3.4M (37.1%), J9299 contributing $1.9M (21.1%), and J9144 contributing $1M (11.2%). This level of concentration around a small set of high-cost drug codes means changes in utilization, pricing, or coverage for these agents would have outsized impact on the provider’s revenue.

The payer mix is essentially single-payer Medicare: with $9.1M in Medicare revenue and no Medicaid billing on file, the practice’s patient and revenue risk is concentrated in the Medicare program rather than spread across public payers. That lack of Medicaid activity suggests the provider’s panel and service lines are oriented toward Medicare beneficiaries receiving specialty oncology infusions.

Operationally the code mix signals an infusion-centric medical oncology operation: top codes are injectable immunotherapies and monoclonal antibodies (J9298 nivolumab and relatlimab-rmbw, J9299 nivolumab, J9144 daratumumab) alongside chemotherapy administration codes (96413, 96401, 96417). The presence of both high-revenue drug codes and frequent administration/infusion codes indicates on-site infusion services and clinical workflows focused on complex biologic therapies rather than primarily office-based management.

Competitive standing is dominant for specific agents: the provider ranks #1 of 5 nationally for J9298 (100th percentile) and #1 of 505 nationally for J9299 (100th percentile), with J9299 specifically labeled an extreme outlier, far above typical national volume for this code. For J9144 the provider ranks #25 of 615 (96th percentile), indicating consistently above-typical national volume for that daratumumab formulation as well.

There are notable statistical signals beyond the top drugs: 96413 is listed as notably above typical national volume (rank #133 of 7514, 98th percentile), and E/M code 99214 also sits well above peers (rank #29455 of 479517, 94th percentile), which together suggest sustained throughput of infusion encounters paired with substantive office-management visits. These elevated percentiles for both drug-administration and E/M codes support the inference of a busy specialty oncology clinic with frequent patient visits and treatment sessions.

Tenure is long-standing: the NPI was enumerated on 2006-07-06 (~20 years ago), indicating roughly two decades of Medicare enrollment that could reflect an established referral footprint and operational stability in the local market. Continued high-volume billing on a set of specialty drug codes suggests the provider has maintained capacity and demand for complex oncology infusions over time.

While dominant on several national ranks, the provider’s revenue profile also concentrates business risk around a few biologic agents and Medicare reimbursement policy: top-3 codes drive 69.4% of Medicare revenue and the practice has no Medicaid billing on file. Payers and contracting teams should treat this provider as a specialized oncology infusion center with high exposure to changes in utilization patterns or reimbursement of the specific high-cost agents J9298 and J9299.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

31 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9298	Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg	23,680	$140	$3.4M
J9299	Injection, nivolumab, 1 mg	83,820	$20	$1.9M
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	26,820	$40	$1M
J9271	Injection, pembrolizumab, 1 mg	23,400	$40	$1M
J9119	Injection, cemiplimab-rwlc, 1 mg	45,500	$20	$910K
J9228	Injection, ipilimumab, 1 mg	6,150	$100	$615K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	860	$110	$96.5K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	660	$100	$68.1K
96401	The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient.	280	$60	$17.1K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	170	$70	$12K

Showing 1–10 of 31

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 31 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Maryland Distribution

William Sharfman — 3 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Maryland

Full comparison — all codes billed, vs. state median

31 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9298	1	10	23,680	$140	$3.4M
J9119	1	10	45,500	$20	$913.1K
J9271	19	60	15,000	$40	$787.6K
J9299	1	20	24,080	$20	$660.6K
J9228	1	10	6,150	$100	$615.8K
J9144	2	30	11,970	$40	$493.5K
96413	8	230	200	$110	$29.6K
99214	1,164	10,270	150	$90	$24.1K
96401	40	190	140	$60	$12.5K
99213	3,288	9,280	100	$60	$12.5K

Showing 1–10 of 31

Related Providers

Other providers that share a Tax Identification Number (TIN) with William Sharfman, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Johns Hopkins University	MD	Emergency Medicine Physician	$0	$21.1M
The Johns Hopkins Hospital	MD	General Acute Care Hospital	$0	$19.9M
Johns Hopkins University	MD	Body Imaging Physician	$0	$15.3M
Johns Hopkins University	MD	Pediatric Emergency Medicine (Pediatrics) Physician	$0	$8.6M
Johns Hopkins University	MD	Internal Medicine Physician	$0	$6.2M
Johns Hopkins University	MD	Cardiovascular Disease Physician	$0	$4.9M
Johns Hopkins University	MD	Hospitalist Physician	$0	$4.5M
Daniel Becker	MD	Neurology Physician	$3.9M	$0
Johns Hopkins University	MD	Clinical Medical Laboratory	$2M	$1.6M
Howard Hauptman	MD	Rheumatology Physician	$2.9M	$0

Nearby Providers

Other providers in the same ZIP code as William Sharfman, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Mosaic Community Services, Inc.	MD	Rehabilitation Clinic/Center	$0	$21.1M
Maxim Healthcare Services, Inc.	MD	Home Health Agency	$0	$18.4M
Stella Maris Inc.	MD	Community Based Hospice Care Agency	$0	$16.9M
Glass Health Programs, Inc.	MD	Substance Use Disorder Rehabilitation Clinic/Center	$479.3K	$8.7M
Mosaic Community Services, Inc.	MD	Adult Mental Health Clinic/Center	$0	$7.1M
Windrush Behavioral Health, LLC	MD	Specialist	$0	$7M
Psych Associates Of Maryland LLC	MD	Psychologist	$0	$5.8M
Katzen Medical Associates, PC	MD	Ophthalmology Physician	$0	$5.6M
Richard Huslig	MD	Hematology & Oncology Physician	$4.9M	$0
Learning And Therapy Corner, LLC	MD	Speech-Language Pathologist	$0	$4.2M

William Sharfman — Billing Profile & Reimbursement Data

Sign up for William Sharfman — Billing Profile & Reimbursement Data policy alerts

William Sharfman — Billing Profile & Reimbursement Data

Sign up for William Sharfman — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References